Results 61 to 70 of about 6,719 (245)

Mapping VEXAS‐associated and rare UBA1 variants in the United Kingdom: Insights from patient cohorts and the general population

open access: yesBritish Journal of Haematology, Volume 208, Issue 1, Page 116-128, January 2026.
VEXAS syndrome is a late‐onset inflammatory disorder with rheumatological and haematological features. Epidemiological studies of VEXAS syndrome so far have been limited. Analysis of various UK cohorts estimates the incidence of VEXAS to be 1.51/100 000, or 171 new cases in the population of men over the age of 50 who are being investigated for myeloid
Ana Martinez Rodriguez   +15 more
wiley   +1 more source

Biodegradable Stents—A New Option for Benign Central Airway Stenosis

open access: yesRespirology, Volume 30, Issue 12, Page 1176-1183, December 2025.
Airway stenting using conventional stents for benign central airway stenosis has considerable complication rates as well as technical difficulties while placing and removing. Polydioxanone biodegradable stents serve as a feasible alternative for individuals requiring temporary airway support.
Oğuz Karcıoğlu   +6 more
wiley   +1 more source

[Relapsing polychondritis].

open access: yesActa otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale, 1993
Relapsing polychondritis is a rare disease of unknown origin consisting in recurrent inflammatory episodes of cartilaginous structures as well as other organs such as the eye, the inner ear and the kidney. Symptoms of autoimmune or rheumatic disorders frequently precede those typical of relapsing polychondritis and thus the contemporaneous presence of ...
Presutti L., Cunsolo E. M., Schiavina M.
openaire   +3 more sources

A novel diagnostic algorithm for chronic and subacute cough [PDF]

open access: yes, 2014
BACKGROUND: Cough remains the most common reason for patients to seek medical attention. We practised a novel diagnostic algorithm for chronic and subacute cough.
Chengzhen Jin, Dan Zhou, Peng Lu
core   +1 more source

Management of an extracranial internal carotid artery aneurysm secondary to relapsing polychondritis

open access: yesJournal of Vascular Surgery Cases and Innovative Techniques, 2020
Extracranial internal carotid artery (EICA) aneurysms make up 1% of peripheral aneurysms and less than 1% of patients who have relapsing polychondritis develop aneurysms.
Kush J. Sharma, MD   +3 more
doaj   +1 more source

Ocular Involvement in Relapsing Polychondritis [PDF]

open access: gold, 2021
Ken Fukuda   +5 more
openalex   +1 more source

Incidence and mortality of relapsing polychondritis in the UK:a population-based cohort study

open access: yes, 2015
OBJECTIVE: Relapsing polychondritis is a rare disease characterized by cartilage inflammation. Our aim was to estimate the incidence, prevalence and mortality of relapsing polychondritis and describe the clinical features of relapsing polychondritis in a
Charlton, Judith   +4 more
core   +2 more sources

Doc, Just Cut My Ears Off—A Case Report of Actinomyces in Bilateral Chronic Auricular Chondritis

open access: yesThe Laryngoscope, Volume 135, Issue 10, Page 3651-3653, October 2025.
Ear piercings can lead to infectious complications, commonly involving Staphylococcus aureus and Pseudomonas aeruginosa . This is the first documented case of bilateral chronic auricular chondritis caused by Actinomyces odontolyticus following cartilage piercings.
Niketna Vivek   +3 more
wiley   +1 more source

Relapsing Polychondritis: A Case Report

open access: yesBoğaziçi Tıp Dergisi, 2022
Relapsing polychondritis (RP) is an uncommon autoimmune disease characterized by repeated and progressive inflammation in cartilage tissue. The auricular cartilage is the location of the most common clinical findings and the most common site of initial ...
Ayşe Ünal Enginar, Cahit Kaçar
doaj   +1 more source

Safety and Effectiveness of Combination Rituximab and Cyclophosphamide Therapy for Treating Pediatric Patients With Severe Manifestations of Rheumatic Disease

open access: yesACR Open Rheumatology, Volume 7, Issue 9, September 2025.
Objective Current practice guidelines recommend the use of either rituximab (RTX) or cyclophosphamide (CYC) for the treatment of severe manifestations of systemic vasculitis or connective tissue disease. Few studies have evaluated safety and efficacy outcomes of combination therapy with RTX and CYC.
Eileen Rife   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy